These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 28066243)

  • 21. The role of rivaroxaban in atrial fibrillation and acute coronary syndromes.
    Reddy P; Giugliano RP
    J Cardiovasc Pharmacol Ther; 2014 Nov; 19(6):526-32. PubMed ID: 24659084
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Anti-Xa Oral Anticoagulant Plasma Concentration Assay in Real Life: Rivaroxaban and Apixaban Quantification in Emergency With LMWH Calibrator.
    Billoir P; Barbay V; Joly LM; Fresel M; Chrétien MH; Le Cam Duchez V
    Ann Pharmacother; 2019 Apr; 53(4):341-347. PubMed ID: 30378443
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy and safety of rivaroxaban compared with warfarin among elderly patients with nonvalvular atrial fibrillation in the Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF).
    Halperin JL; Hankey GJ; Wojdyla DM; Piccini JP; Lokhnygina Y; Patel MR; Breithardt G; Singer DE; Becker RC; Hacke W; Paolini JF; Nessel CC; Mahaffey KW; Califf RM; Fox KA;
    Circulation; 2014 Jul; 130(2):138-46. PubMed ID: 24895454
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Rivaroxaban as an Antithrombotic Agent in a Patient With ST-Segment Elevation Myocardial Infarction and Left Ventricular Thrombus: A Case Report.
    Seecheran R; Seecheran V; Persad S; Seecheran NA
    J Investig Med High Impact Case Rep; 2017; 5(1):2324709617697991. PubMed ID: 28540312
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Risk Factors for Rivaroxaban-Related Bleeding Events-Possible Role of Pharmacogenetics: Case Series.
    Šimičević L; Slišković AM; Kirhmajer MV; Ganoci L; Holik H; Palić J; Samardžić J; Božina T
    Pharmacy (Basel); 2023 Feb; 11(1):. PubMed ID: 36827667
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical Pharmacokinetics and Pharmacodynamics of Direct Oral Anticoagulants in Patients with Renal Failure.
    Padrini R
    Eur J Drug Metab Pharmacokinet; 2019 Feb; 44(1):1-12. PubMed ID: 30167998
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Gastrointestinal Bleeding in Patients With Atrial Fibrillation Treated With Rivaroxaban or Warfarin: ROCKET AF Trial.
    Sherwood MW; Nessel CC; Hellkamp AS; Mahaffey KW; Piccini JP; Suh EY; Becker RC; Singer DE; Halperin JL; Hankey GJ; Berkowitz SD; Fox KAA; Patel MR
    J Am Coll Cardiol; 2015 Dec; 66(21):2271-2281. PubMed ID: 26610874
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Influence of genetic variation in CYP3A4 and ABCB1 on dose decrease or switching during simvastatin and atorvastatin therapy.
    Becker ML; Visser LE; van Schaik RH; Hofman A; Uitterlinden AG; Stricker BH
    Pharmacoepidemiol Drug Saf; 2010 Jan; 19(1):75-81. PubMed ID: 19802823
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Downregulation of ABCB1 gene in patients with total hip or knee arthroplasty influences pharmacokinetics of rivaroxaban: a population pharmacokinetic-pharmacodynamic study.
    Zdovc J; Petre M; Pišlar M; Repnik K; Mrhar A; Vogrin M; Potočnik U; Grabnar I
    Eur J Clin Pharmacol; 2019 Jun; 75(6):817-824. PubMed ID: 30725221
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dose-finding study of rivaroxaban in hemodialysis patients.
    De Vriese AS; Caluwé R; Bailleul E; De Bacquer D; Borrey D; Van Vlem B; Vandecasteele SJ; Emmerechts J
    Am J Kidney Dis; 2015 Jul; 66(1):91-8. PubMed ID: 25804678
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Bodyweight-adjusted rivaroxaban for children with venous thromboembolism (EINSTEIN-Jr): results from three multicentre, single-arm, phase 2 studies.
    Monagle P; Lensing AWA; Thelen K; Martinelli I; Male C; Santamaría A; Samochatova E; Kumar R; Holzhauer S; Saracco P; Simioni P; Robertson J; Grangl G; Halton J; Connor P; Young G; Molinari AC; Nowak-Göttl U; Kenet G; Kapsa S; Willmann S; Pap AF; Becka M; Twomey T; Beyer-Westendorf J; Prins MH; Kubitza D;
    Lancet Haematol; 2019 Oct; 6(10):e500-e509. PubMed ID: 31420317
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Safety of Non-Vitamin K Antagonist Oral Anticoagulants in Clinical Practice: Focus on Rivaroxaban in Stroke Prevention in Patients With Atrial Fibrillation.
    Sanmartín-Fernández M; Marzal-Martín D
    Clin Appl Thromb Hemost; 2017 Oct; 23(7):711-724. PubMed ID: 27624737
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of the short-term risk of bleeding and arterial thromboembolic events in nonvalvular atrial fibrillation patients newly treated with dabigatran or rivaroxaban versus vitamin K antagonists: a French nationwide propensity-matched cohort study.
    Maura G; Blotière PO; Bouillon K; Billionnet C; Ricordeau P; Alla F; Zureik M
    Circulation; 2015 Sep; 132(13):1252-60. PubMed ID: 26199338
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Abnormal uterine bleeding in VTE patients treated with rivaroxaban compared to vitamin K antagonists.
    De Crem N; Peerlinck K; Vanassche T; Vanheule K; Debaveye B; Middeldorp S; Verhamme P; Peetermans M
    Thromb Res; 2015 Oct; 136(4):749-53. PubMed ID: 26272306
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effectiveness and safety of reduced dose non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study.
    Nielsen PB; Skjøth F; Søgaard M; Kjældgaard JN; Lip GY; Larsen TB
    BMJ; 2017 Feb; 356():j510. PubMed ID: 28188243
    [No Abstract]   [Full Text] [Related]  

  • 36. Comparative pharmacokinetics of vitamin K antagonists: warfarin, phenprocoumon and acenocoumarol.
    Ufer M
    Clin Pharmacokinet; 2005; 44(12):1227-46. PubMed ID: 16372822
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Perioperative anticoagulation with NOAC using the example of rivaroxaban].
    Koscielny J; von Heymann C; Bauersachs R; Mouret P; Antz M
    MMW Fortschr Med; 2017 Mar; 159(Suppl 4):18-23. PubMed ID: 28244023
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and Safety of Rivaroxaban Versus Warfarin in Patients Taking Nondihydropyridine Calcium Channel Blockers for Atrial Fibrillation (from the ROCKET AF Trial).
    Washam JB; Hellkamp AS; Lokhnygina Y; Piccini JP; Berkowitz SD; Nessel CC; Becker RC; Breithardt G; Fox KAA; Halperin JL; Hankey GJ; Mahaffey KW; Singer DE; Patel MR;
    Am J Cardiol; 2017 Aug; 120(4):588-594. PubMed ID: 28645473
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Recurrent venous thrombosis under rivaroxaban and carbamazepine for symptomatic epilepsy.
    Stöllberger C; Finsterer J
    Neurol Neurochir Pol; 2017; 51(2):194-196. PubMed ID: 28215696
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects on bone metabolism markers and arterial stiffness by switching to rivaroxaban from warfarin in patients with atrial fibrillation.
    Namba S; Yamaoka-Tojo M; Kakizaki R; Nemoto T; Fujiyoshi K; Hashikata T; Kitasato L; Hashimoto T; Kameda R; Meguro K; Shimohama T; Tojo T; Ako J
    Heart Vessels; 2017 Aug; 32(8):977-982. PubMed ID: 28233091
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.